Related Experiment Videos
Amelioration of experimental colitis by thalidomide
1Department of Gastroenterology, Sackler Faculty of Medicine, Tel Aviv University, Israel.
The Israel Medical Association Journal : IMAJ
|September 29, 2001
Summary
Thalidomide effectively reduced experimental colitis in rats by decreasing inflammation and tumor necrosis factor alpha (TNF alpha) levels. Further studies are needed to explore this mechanism for treating inflammatory bowel diseases.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Iodoacetamide administration in rats is a model for inducing colitis.
- Thalidomide exhibits anti-inflammatory properties, potentially by suppressing tumor necrosis factor alpha (TNF alpha).
- TNF alpha plays a significant role in the inflammation associated with Crohn's disease.
Purpose of the Study:
- To investigate the therapeutic effects of thalidomide on experimental colitis induced by iodoacetamide in a rat model.
Main Methods:
- Colitis was induced in rats using intracolonic iodoacetamide.
- Rats received daily oral thalidomide (50 mg/kg) for seven days.
- Colonic tissues and serum were analyzed for inflammation markers, including myeloperoxidase activity and TNF alpha levels.
Main Results:
- Thalidomide treatment significantly reduced colonic wet weight, lesion area, myeloperoxidase activity, and serum TNF alpha levels compared to controls.
- Histological examination revealed a marked decrease in colonic inflammation in thalidomide-treated rats.
- The observed reductions were statistically significant (P < 0.05).
Conclusions:
- Thalidomide demonstrates efficacy in reducing iodoacetamide-induced colitis in rats.
- The anti-inflammatory effect of thalidomide is likely mediated through the inhibition of TNF alpha.
- Further research is warranted to elucidate the precise mechanisms and therapeutic potential of thalidomide for colitis.